03:43 PM EST - Aeterna Zentaris Inc. : announced that Phase 3 results for its ghrelin agonist, AEZS-130, show that it has promise as a safe and simple oral diagnostic test for adult growth hormone deficiency (AGHD), with accuracy comparable to available testing procedures. Aeterna Zentaris Inc.
shares T.AEZ are trading unchanged at $2.34.
